BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
- Conditions
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 822
- Registration Number
- NCT05850520
- Locations
- 🇨🇳
Qilu Hosp., Shandong Univ., Jinan, Shandong, China
🇨🇳Capital Medical University (CMU) - Beijing Tongren Hospital, Beijing, China
🇨🇳Beijing Tongren Hospital, Capital Medical University (West), Beijing, China
An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 818
- Registration Number
- NCT05839951
- Locations
- 🇺🇸
Many locations, Whippany, New Jersey, United States
A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT05800444
- Locations
- 🇯🇵
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Japan
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 750
- Registration Number
- NCT05794906
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center-Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States
🇧🇷Hospital São Rafael, Salvador, Bahia, Brazil
🇧🇷Assistência Multidisciplinar em Oncologia (AMO), Salvador, Bahia, Brazil
An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan
- Conditions
- Interventions
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 46621
- Registration Number
- NCT05793281
- Locations
- 🇯🇵
Many Locations, Multiple Locations, Japan
An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
- Conditions
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2400
- Registration Number
- NCT05728502
- Locations
- 🇨🇳
Chinese Registries, Multiple Locations, Many Locations, China
An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15948
- Registration Number
- NCT05703880
- Locations
- 🇺🇸
Optum electronic health records (EHR) database, Eden Prairie, Minnesota, United States
🇺🇸OM1 Real-World Data Cloud (RWDC), Boston, Massachusetts, United States
A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 75
- Registration Number
- NCT05705258
- Locations
- 🇯🇵
Many locations, Multiple Locations, Japan
A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 200
- Registration Number
- NCT05705271
- Locations
- 🇮🇳
Dr Balabhai Nanavati Hospital, Mumbai, Maharashtra,, Maharashtra, India
🇮🇳Bhate Hospital, Karnataka, Belagavi, India
🇮🇳Kempegowda Institute of Medical Sciences Hospital & R C, Bangalore, Karnataka, India
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12300
- Registration Number
- NCT05686070
- Locations
- 🇦🇷
Sanatorio Parque | Departamento de Neurologia, Rosario, Santa Fe, Argentina
🇦🇷Centro Estudios Médicos e Invest. Clínicas "Dr. N. Quirno", Buenos Aires, Argentina
🇦🇷Sanatorio Allende | Departamento de Investigación Clínica, Córdoba, Argentina